University of Miami Initiates CAR-T Clinical Trial in Myasthenia Gravis

Neuromuscular experts with the University of Miami Health System and the Miller School of Medicine will launch a Phase 1/2 clinical trial (NCT04146051) using the CAR-T drug, Descartes-08, to treat patients with generalized myasthenia gravis. Generalized myasthenia gravis (GMG) is a rare disease and a chronic autoimmune condition in which auto-antibodies attack specific proteins at the

Read More


AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR-T cells for Patients with Advanced, Refractory Thyroid Cancer

AffyImmune Therapeutics, an emerging leader in CAR-T therapies, today announced FDA approval of the company’s investigational new drug (IND) application for AIC100, an affinity-tuned CAR-T cell that received Orphan designation for advanced thyroid cancer. The trial: Phase I study of AIC100 in relapsed and or refractory advanced thyroid cancer and anaplastic thyroid cancer, is sponsored by Weill

Read More


CARsgen Announces Investigational CAR-T Therapy CT053, after PRIME eligibility by EMA, Granted RMAT Designation by the U.S. FDA for R/R Multiple Myeloma

CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of

Read More


CAR-T cells therapy in Italy. Interview with Prof. Locatelli, Chairman of the Italian Project Group

“The Italian government has decided to invest 60 million euros on CAR-T therapies, 10 million for each of the 6 pharmaceutical workshops”. This was stated by Health Minister Roberto Speranza, explaining to the joint committees of the Senate and the House the program lines of his department. CAR-T cell therapy consists of genetic manipulation of

Read More


The Italian way to CAR-T cells.

The announcement by the Health Minister Speranza: “60 million to 6 workshops to produce Car-T against cancer” The Car-t therapies are “a strategic segment on which the government has decided to invest 60 million euros, foreseeing 10 million for each pharmaceutical workshop”, or high-tech laboratories in which the patient’s immune cells against tumors are modified.

Read More


Potency of CAR T-Cell Therapy for Myeloma May Vary by Disease Stage

Source CancerNetwork CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease, according to study results1 published in Blood Advances. “CAR T cells directed against the B-cell maturation antigen (BCMA) have demonstrated impressive initial results, but available data suggest that most patients with initial responses

Read More


University of Pennsylvania Announces Completion of Exclusive R&D Alliance With Novartis and Development of New Focused Relationship

Penn to Broaden Pathways for Development of New CAR T Cell Therapies Following a landmark, first-of-its-kind collaboration that spawned the global CAR T cell therapy industry, the University of Pennsylvania and Novartis have concluded their seven-year research and development alliance, which resulted in the world’s first approved gene therapy for cancer. They will continue to

Read More


CAR T-Cell Therapy May Be Harnessed to Treat Heart Disease

Penn study finds immunotherapy reduces cardiac fibrosis and restores heart function in mice after cardiac injury CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients’ own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition: heart disease. In a first-of-its-kind study, published today in Nature, researchers

Read More


Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

The inhibitory receptors PD-1, Tim-3, and Lag-3 are highly expressed on tumor-infiltrating lymphocytes and compromise their antitumor activity. For efficient cancer immunotherapy, it is important to prevent chimeric antigen receptor T (CAR-T)-cell exhaustion. Here we downregulate these three checkpoint receptors simultaneously on CAR-T cells and that show the resulting PTL-CAR-T cells undergo epigenetic modifications and better control

Read More


Clinical lessons learned from the first leg of the CAR T cell journey

Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of cancer. This experience has illuminated some generalizable requirements for CAR T cell efficacy as well as the interplay

Read More